CKD-FIX: a randomised, controlled trial of allopurinol in the slowing of kidney disease progression

CKD-FIX：别嘌呤醇减缓肾脏疾病进展的随机对照试验

• 批准号: nhmrc : GNT1043203
• 负责人: A/Pr Gopala Rangan
• 金额: $ 191.71万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/ckd-fix-randomised-disease-progression/1344428
• 关键词: CKD; FIX; randomised; controlled; trial

Chronic kidney disease (CKD) is a major public health problem affecting over 1.5 million Australians and is associated with increased risk of death, heart disease and progression to end-stage kidney disease (ESKD). Current treatments to slow progression to ESKD are limited. The CKD-FIX trial aims to find out whether treatment with allopurinol, a commonly used drug for gout prevention, safely and effectively slows CKD progression. This could lead to significant health and economic benefits.

慢性肾脏疾病（CKD）是影响超过150万澳大利亚人的主要公共卫生问题，与死亡，心脏病和进展为终末期肾脏疾病（ESKD）的风险增加有关。目前减缓ESKD进展的治疗方法有限。CKD-FIX试验的目的是找出用别嘌呤醇（一种预防痛风的常用药物）治疗是否安全有效地减缓CKD进展。这可能带来重大的健康和经济效益。